|Outpatient electronic health records and the clinical care and outcomes of patients with diabetes mellitus.|
|PMID: 23027319 Owner: NLM Status: MEDLINE|
|BACKGROUND: Physicians can receive federal payments for meaningful use of complete certified electronic health records (EHRs). Evidence is limited on how EHR use affects clinical care and outcomes.
OBJECTIVE: To examine the association between use of a commercially available certified EHR and clinical care processes and disease control in patients with diabetes.
DESIGN: Quasi-experimental design with outpatient EHR implementation sequentially across 17 medical centers. Multivariate analyses adjusted for patient characteristics, medical center, time trends, and facility-level clustering.
SETTING: Kaiser Permanente Northern California, an integrated delivery system.
PATIENTS: 169 711 patients with diabetes mellitus.
INTERVENTION: Use of a commercially available certified EHR.
MEASUREMENTS: Drug treatment intensification and hemoglobin A(1c) (HbA(1c)) and low-density lipoprotein cholesterol (LDL-C) testing and values.
RESULTS: Use of an EHR was associated with statistically significant improvements in treatment intensification after HbA(1c) values of 9% or greater (odds ratio, 1.10 [95% CI, 1.05 to 1.15]) or LDL-C values of 2.6 to 3.3 mmol/L (100 to 129 mg/dL) (odds ratio, 1.06 [CI, 1.00 to 1.12]); increases in 1-year retesting for HbA(1c) and LDL-C levels among all patients, with the most dramatic change among patients with the worst disease control (HbA(1c) levels ≥9% or LDL-C levels ≥3.4 mmol/L [≥130 mg/dL]); and decreased 90-day retesting among patients with HbA(1c) levels less than 7% or LDL-C levels less than 2.6 mmol/L (<100 mg/dL). The EHR was also associated with statistically significant reductions in HbA(1c) and LDL-C levels, with the largest reductions among patients with the worst control (0.06-mmol/L [2.19-mg/dL] reduction among patients with baseline LDL-C levels ≥3.4 mmol/L [≥130 mg/dL]; P < 0.001).
LIMITATION: The EHR was implemented in a setting with strong baseline performance on cardiovascular care quality measures.
CONCLUSION: Use of a commercially available certified EHR was associated with improved drug treatment intensification, monitoring, and physiologic control among patients with diabetes, with greater improvements among patients with worse control and less testing in patients already meeting guideline-recommended glycemic and lipid targets.
PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases.
|Mary Reed; Jie Huang; Ilana Graetz; Richard Brand; John Hsu; Bruce Fireman; Marc Jaffe|
Related Documents :
|24913359 - Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in ad...
23375819 - Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kid...
23379629 - Incidence and outcome of contrast-associated acute kidney injury in a mixed medical-sur...
23600049 - Treatment of chronic hepatitis c in end stage renal disease: experience at a tertiary c...
23925819 - Polypharmacy and comorbidity are associated with a lower early virologic response in he...
24666889 - The consequences of sudden fluid shifts on body composition in critically ill patients.
20580619 - Economic burden associated with the use of generic antiepileptic drugs in the united st...
11560229 - Anesthetic management for coronary bypass patients on hemodialysis: report of 4 patients.
23159229 - The influence of vkorc1 and cyp2c9 gene sequence variants on the stability of maintenan...
|Type: Journal Article; Research Support, N.I.H., Extramural|
|Title: Annals of internal medicine Volume: 157 ISSN: 1539-3704 ISO Abbreviation: Ann. Intern. Med. Publication Date: 2012 Oct|
|Created Date: 2012-10-02 Completed Date: 2012-12-04 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 0372351 Medline TA: Ann Intern Med Country: United States|
|Languages: eng Pagination: 482-9 Citation Subset: AIM; IM|
|Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Ambulatory Care / standards*
Cholesterol, LDL / blood
Diabetes Mellitus / blood, drug therapy*
Electronic Health Records / standards*
Hemoglobin A, Glycosylated / analysis
Hypoglycemic Agents / administration & dosage, therapeutic use*
Hypolipidemic Agents / therapeutic use
Outcome Assessment (Health Care)*
|R01 DK085070/DK/NIDDK NIH HHS; R01DK085070/DK/NIDDK NIH HHS|
|0/Cholesterol, LDL; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Hypolipidemic Agents|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Two novel equations to estimate kidney function in persons aged 70 years or older.
Next Document: [Writing for the HaMiPla].